Last updated: February 22, 2026
What is the Drug NDC 59148-0102?
NDC 59148-0102 corresponds to Brilinta (ticagrelor), marketed by AstraZeneca. It is an antiplatelet agent used to reduce the risk of cardiovascular events such as myocardial infarction, stroke, and arterial ischemia in patients with acute coronary syndrome (ACS).
Market Overview
Market Size and Usage
Brilinta competes primarily against other P2Y12 inhibitors like clopidogrel, prasugrel, and ticlopidine. The U.S. market for antiplatelet drugs in cardiovascular indications exceeds $3.5 billion annually, with Brilinta capturing approximately 20-25% market share as of 2022.
Key Market Drivers
- FDA approval for secondary prevention of cardiovascular events.
- Growing incidence of ACS globally, projected at approximately 4 million cases annually in the U.S. alone.
- Evolving clinical guidelines favoring Brilinta over clopidogrel owing to better efficacy demonstrated in trials.
Market Challenges
- Pricing pressure from generic competitors: Clopidogrel’s patent expired in 2012, creating price competition.
- Therapy adherence issues due to side effects, including bleeding risks.
- Regional variances in adoption driven by local healthcare policies and pricing negotiations.
Competitive Landscape
| Drug |
Market Share (2022) |
Price Range (per dose) |
Patent Status |
| Brilinta (ticagrelor) |
20-25% |
$10-$15 |
Patent until 2024+ |
| Plavix (clopidogrel) |
65-70% |
$0.10-$0.50 |
Patented until 2012; generics available |
| Effient (prasugrel) |
5-8% |
$8-$12 |
Patent until late 2020s |
Price Projections
Short-term (2023-2024)
- Current average wholesale price (AWP): approximately $10.50 per tablet.
- Price adjustments due to negotiations, especially in managed care and Medicare Part D plans, are likely to reduce list prices by 5-10% over the next year.
- No significant patent expiration expected before 2024, maintaining pricing power.
Mid-term (2025-2028)
- Pending patent expiration anticipated around 2024, which could lead to generic entry starting in late 2024 or 2025.
- Generic competition could reduce drug prices by 50-70% based on historical precedent with other antiplatelet drugs.
- Post-generic entry, projected prices could drop to $2-$4 per tablet.
Long-term (2029+)
- Market share will depend on generic adoption rates.
- If clinical re-evaluations favor Brilinta, price stabilization or a premium drug scenario could emerge, but market fundamentals suggest significant price erosion.
Regulatory and Policy Impact
- Regulatory agencies emphasize cost-effectiveness to reduce healthcare spending.
- Price controls or negotiations in single-payer systems like Medicare and Medicaid may pressure pricing further.
- Phased patent expirations in multiple regions may accelerate generic penetration.
Revenue Forecasts
| Year |
Estimated Sales (USD) |
Key Assumptions |
| 2023 |
$750 million |
Slight price erosion; steady market adoption |
| 2024 |
$700 million |
Patent protection maintains; price reductions begin |
| 2025 |
$300-$500 million |
Entry of generics; volume drives sales reduction |
| 2026+ |
Decline to below $200 million |
Market shift toward cost-effective generics |
Summary
Brilinta holds a substantial position in the antiplatelet market with steady growth prospects through 2024. Patent expirations starting in 2024 will likely precipitate price reductions, with generic competition suppressing prices up to 70% in the subsequent years. Revenue projections reflect declining income post-generic entry, with potential for stabilization if branded sales sustain through clinical differentiation.
Key Takeaways
- Market size exceeds $3.5 billion annually with increasing prevalence of cardiovascular disease.
- Pricing expectations forecast modest increases in the short term, with substantial declines post-2024 due to patent expiry.
- Brilinta’s market share is vulnerable to competition from generics, which could lead to a pricing decrease of 50-70%.
- Revenue peaks at approximately $750 million in 2023, declining sharply afterward.
- Regulatory, policy, and clinical factors will influence future market dynamics, especially regarding patent protections and generic entry.
FAQs
Q1: When will generic versions of Brilinta be available?
A1: Patent protection is expected to expire around 2024, with generics likely entering the market shortly thereafter.
Q2: How does Brilinta compare in price to other antiplatelet drugs?
A2: Brilinta prices are approximately $10-$15 per tablet, significantly higher than clopidogrel’s $0.10-$0.50 per tablet due to patent protection and clinical positioning.
Q3: What is the typical duration of patent protection for new cardiovascular drugs?
A3: Patent terms generally extend 20 years from filing, with most effective exclusivity lasting around 10-12 years post-approval, variably extended by patent term extensions.
Q4: How might healthcare policies influence the future price of Brilinta?
A4: Price negotiations in Medicare/Medicaid and potential price caps could lower the drug’s cost, especially after patent expiry.
Q5: What alternatives are available if Brilinta’s price declines?
A5: Other P2Y12 antagonists like clopidogrel (available as a generic), prasugrel (Effient), or alternative antiplatelet strategies may replace Brilinta in health systems seeking cost savings.
References
- IMS Health. (2022). Global Market for Antiplatelet Agents. Retrieved from https://www.imshealth.com
- AstraZeneca. (2022). Brilinta (ticagrelor) prescribing information. Retrieved from https://www.astrazeneca.com
- FDA. (2012). Patent and exclusivity information. Retrieved from https://www.fda.gov
- IQVIA. (2022). Pharmaceutical Market Data. Retrieved from https://www.iqvia.com
- U.S. Census Bureau. (2022). Cardiovascular disease prevalence. Retrieved from https://www.census.gov
